Clindamycin and nicotinic neuromuscular transmission.

Schulze, J; Toepfer, M; Schroff, K C; Aschhoff, S; Remien, J; Müller-Felber, W; Endres, S · Lancet · 1999

case_report · Level V

Where this comes from

Abstract

Upon clindamycin treatment a patient with Parkinson's disease showed marked tremor improvement which may be explained by clindamycin's ability to inhibit in-vitro nicotinergic, but not muscarinic signal transmission.

Medical subject headings